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1. INTRODUCTION {#cam42497-sec-0001}
===============

Gastric cancer (GC) is the fifth common cancer (6.8%) in the world and the third leading cause of death related to cancer (8.8%) worldwide.[1](#cam42497-bib-0001){ref-type="ref"} In fact, the complicated interaction between *Helicobacter pylori* (*H pylori*) infection and genetic, epigenetic, and environmental factors results in GC.[2](#cam42497-bib-0002){ref-type="ref"} Gastric adenocarcinoma is the prominent type of GC, which is classified into two major histological subtypes of intestinal and diffuse adenocarcinoma according to Lauren\'s classification, reflecting its pathogenesis.[3](#cam42497-bib-0003){ref-type="ref"} There are two GC subtypes, cardia (occurring in the 1‐cm (cm) proximal and 2‐cm distal area of the esophago‐gastric junction) gastric adenocarcinoma (CGA) and noncardia (distal: involving the distal and middle parts of the stomach) gastric adenocarcinoma (NCGA).[4](#cam42497-bib-0004){ref-type="ref"} In 2012, 260 000 CGA cases (age‐standardised rate (ASR) 3.3 per 100 000) and 691 000 NCGA cases (ASR 8.8) were reported all over the world. The greatest regional rates of both GC subsites were in Eastern/Southeastern Asia (in men, ASRs: 8.7 and 21.7 for CGA and NCGA, respectively). NCGA was observed more commonly than CGA with a mean ratio of 2:1 in most countries, but in some populations, the rates of NCGA incidence were less than the global mean.[5](#cam42497-bib-0005){ref-type="ref"} Ardabil Province in Northwest of Iran has the highest CGA rates in the world. In Ardabil, over one‐third of the GC occurs in the cardia region of the stomach having only 5%‐10% of the whole stomach, and the ASRs for CGA are 26.4 and 8.6 for males and females, respectively.[6](#cam42497-bib-0006){ref-type="ref"}

The etiology of adenocarcinoma of the cardia and the gastroesophageal junction (GEJ) is not known and is doubted. It is thought that CGA is distinct from adenocarcinomas located in the esophagus or distal stomach, both epidemiologically and biologically.[7](#cam42497-bib-0007){ref-type="ref"} Moreover, CGA is often identified in the advanced stage having a poor prognosis. In this paper, we would like to ascertain the possible role of GC family history, lifestyle, demographics, gastroesophageal reflux disease, *H pylori* infection, and multiple genetic and epigenetic risk factors as well as several predisposing conditions in susceptibility to CGA. Therefore, understanding risk and the role of these factors in etiology of CGA can inform clinical practice and counseling for risk reduction.

2. FAMILY HISTORY {#cam42497-sec-0002}
=================

Most GCs are sporadic; however, nearly 10% represents familial aggregation with an unclear molecular basis. Hereditary cancers constitute less than 3% of all stomach cancers and are recessed into the three autosomal dominant syndromes: hereditary diffuse GC (HDGC), familial intestinal GC, and gastric adenocarcinoma and proximal polyposis of the stomach.[8](#cam42497-bib-0008){ref-type="ref"} HDGC is the most commonly known familial GC and is characterized by CDH1 deletion. However, it is rare, not taking into account a large proportion of family clustering.[9](#cam42497-bib-0009){ref-type="ref"} The incidence rate of HDGC in the cardia and noncardia subsites of the stomach is also not clear.

Family history of GC raises the risk of its development, with risks ranging from 1.3 to 3.0 for the first‐degree relatives of GC cases. GC development under 50 years of age is probably followed by family history.[10](#cam42497-bib-0010){ref-type="ref"} People with a positive paternal family history were at higher risk of GC compared to positive maternal family history.[11](#cam42497-bib-0011){ref-type="ref"} Coexistence of two risk factors including a positive family history and infection with a CagA‐positive *H pylori* isolate could increase more than 16‐fold risk of NCGA and eightfold total risk of CGA.[12](#cam42497-bib-0012){ref-type="ref"} Thus, identifying inherited parameters among subjects with GC family histories is an important step for due diagnosis and management of the disease.

3. DEMOGRAPHIC AND BEHAVIORAL FACTORS {#cam42497-sec-0003}
=====================================

The GC incidence increases with age. The median age for GC diagnosis is 70.[13](#cam42497-bib-0013){ref-type="ref"} Compared with women, men had greater rates for both the subsites, especially for CGA (male‐to‐female ratio 3:1).[5](#cam42497-bib-0005){ref-type="ref"} This marked difference is likely to be due to endogenous factors, such as reproductive hormones, different prevalence of central obesity between two sexes, or different premenopausal iron status. However, it cannot be explained by different smoking histories.[14](#cam42497-bib-0014){ref-type="ref"} Estrogen---the female sex hormone---is a suppressor of the inflammatory response and cytokine production in certain tissues, thus likely having similar effects in the upper gastrointestinal (GI) tract. In addition, lower body iron stored during their reproductive years in females might change the degree of DNA damage caused by chronic inflammation. Male predominance of upper GI adenocarcinomas is also related to the intestinal subtype rather than tumor subsite because of delayed development of this subtype in females before 50‐60 years.[15](#cam42497-bib-0015){ref-type="ref"}

A meta‐analysis study revealed that smoking was associated with CGA and the relative risk (RR) was 1.87. RR rose from 1.3 for the lowest intake to 1.7 for about 30 cigarettes per day.[16](#cam42497-bib-0016){ref-type="ref"} Risks of CGA were higher than those of NCGA in former, moderate, and high‐intensity cigarette smokers.[17](#cam42497-bib-0017){ref-type="ref"} It also relates opium use to a higher risk of GC[18](#cam42497-bib-0018){ref-type="ref"} with an augmented CGA risk (OR = 2.8).[19](#cam42497-bib-0019){ref-type="ref"} The obesity prevalence, indicated by body mass index (BMI ≥30 kg/m^2^), has increased over the past two decades. Fat is metabolically active and generates many compounds that move in the body. These products (eg, insulin‐like growth factor and leptin) are related to malignancies, probably via inducing pro‐growth changes in the cycle of a cell, declined cell death, and pro‐neoplastic cellular variations.[20](#cam42497-bib-0020){ref-type="ref"} Meta‐analysis showed that risen BMI correlated with the CGA risk (CGA, summary relative risk, SRRs = 1.21 and 1.82 for overweight and obesity, respectively, but not with NCGA (NCGA; SRRs = 0.93 and 1.00 for overweight and obesity, respectively.[21](#cam42497-bib-0021){ref-type="ref"} A meta‐analysis revealed a 21% decline in GC risk, in those having higher physical activity compared to the least active ones. This risk decline was reported for both NCGA (37% risk reduction) and CGA (20% risk reduction).[22](#cam42497-bib-0022){ref-type="ref"}

4. GASTROESOPHAGEAL REFLUX DISEASE {#cam42497-sec-0004}
==================================

Gastroesophageal reflux disease (GERD), troublesome and recurrent heartburn and regurgitation, is known as a primary risk factor for upper gastrointestinal cancers. Significant associations have been found between CGA and GERD, with two‐ to fourfolds of increased risk in many studies; however, not all studies confirm it.[23](#cam42497-bib-0023){ref-type="ref"}, [24](#cam42497-bib-0024){ref-type="ref"} The increase in the occurrence of CGA in the Western world was elaborated by increasing GERD incidence and obesity.[25](#cam42497-bib-0025){ref-type="ref"} CGA was related with gastric atrophy (OR = 3.92) and GERD symptoms (OR = 10.08), hence results show two different etiologies of CGA, one resulting from intense atrophic gastritis (intestinal or diffuse subtype) as NCGA and another from GERD (intestinal subtype).[23](#cam42497-bib-0023){ref-type="ref"}, [26](#cam42497-bib-0026){ref-type="ref"} Endoscopic screening of men with chronic GERD symptoms (≥5 years) who have at least two additional risk factors (eg age \>50 years, central obesity, past or current history of smoking, White race, or family history of Barrett esophagus) is suggested by current guidelines.[27](#cam42497-bib-0027){ref-type="ref"} However, there are junctional cancers in patients who never had typical reflux diseases, largely explained by two entities of partial hiatus hernia and intrasphincteric reflux.[28](#cam42497-bib-0028){ref-type="ref"} Hiatal hernia (HH) is a significant independent risk factor for CGA and esophageal adenocarcinoma. HH in combination with reflux symptoms was strongly associated with the risk of esophageal adenocarcinomas (OR = 8.11). This association was more modest for CGA (OR = 2.93).[29](#cam42497-bib-0029){ref-type="ref"} It has also been shown that in the asymptomatic, moderately overweight population with no reflux, there are cardiac mucosal lengthening and proximal extension of gastric acid within the lower esophageal sphincter, thus likely causing the observed change in the cardiac mucosa. These changes may be related to the etiology of CGA and GEJ, often seen in people without a history of reflux disease.[30](#cam42497-bib-0030){ref-type="ref"}, [31](#cam42497-bib-0031){ref-type="ref"}

5. *Helicobacter pylori* INFECTION {#cam42497-sec-0005}
==================================

The main risk factor of intestinal metaplasia, chronic atrophic gastritis, and gastric adenocarcinoma is *H pylori* that colonizes the human stomach.[32](#cam42497-bib-0032){ref-type="ref"} Studies on Asian countries have revealed a higher positive association between *H pylori* infection and CGA, while some other studies of Western countries have reported no association or even inverse association.[33](#cam42497-bib-0033){ref-type="ref"}, [34](#cam42497-bib-0034){ref-type="ref"} The meta‐analysis provided evidence for a positive association between CGA and *H pylori* infection. For CGA, summary RR was 1.08 (95% CI 0.83‐1.40), greater in high‐risk (RR = 1.98; 95% CI 1.38‐2.83) than in low‐risk situations (RR = 0.78; 95% CI 0.63‐0.97).[35](#cam42497-bib-0035){ref-type="ref"} Individual antigen testing has revealed that CagA positivity is associated with an increased risk of CGA and NCGA, which is in line with other studies conducted in Asian populations.[36](#cam42497-bib-0036){ref-type="ref"} The *vacA* c1 genotype of *H pylori* has strongly increased the risk of CGA (OR = 14.11). *H pylori vacA* c1 genotype is also thought to be the primary bacterial biomarker for the prediction of CGA risk in Iranian males aged \>55.[37](#cam42497-bib-0037){ref-type="ref"} In contrast, the *vacA* c2 genotype, particularly in combination with *cag*PAI genotypes (ie *cagH*, *cagL*, *cagG*, and *orf17*), showed strong inverse associations with the risk of CGA and non‐CGA, indicating a coordinated relationship between the *vacA* c2 and *cag*PAI genotypes.[38](#cam42497-bib-0038){ref-type="ref"}

6. GENETIC RISK FACTORS {#cam42497-sec-0006}
=======================

6.1. New molecular subtypes of GC {#cam42497-sec-0007}
---------------------------------

Recently, four molecular subtypes of GC have been determined by the Cancer Genome Atlas (TCGA) project, which include Epstein‐Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN).[39](#cam42497-bib-0039){ref-type="ref"} CIN subtype, which mostly occurs in the esophago‐gastric junction (EGJ)/cardia, represents at least 50% of GCs.[40](#cam42497-bib-0040){ref-type="ref"} It is related to intestinal‐type histology, showing elevated frequency in the EGJ/cardia, according to TCGA characterization (65%).[41](#cam42497-bib-0041){ref-type="ref"} Furthermore, the Asian Cancer Research Group (ACRG) has proposed other molecular classification, including mesenchymal subgroup (MSS/EMT), microsatellite instability subgroup (MSI), Microsatellite Stable *TP53*‐positive (MSS/TP53^+^, corresponding to EBV^+^ subtype by TCGA), and Microsatellite Stable *TP53*‐negative tumors (MSS/TP53^−^, corresponding to CIN subtype by TCGA). Microsatellite‐unstable tumors, which occur in the antrum, are hypermutated intestinal‐subtype tumors having the best prognosis and the lowest frequency of recurrence (22%) of the four subtypes. The mesenchymal‐like type, including diffuse‐subtype tumors, which have the tendency to occur at an earlier age, shows the worst prognosis and the highest recurrence frequency (63%) of the four subtypes.[42](#cam42497-bib-0042){ref-type="ref"}

These classifications open new horizons for identification of relevant genomic subsets for precision oncology using highly complex methodologies, including genomic screening and molecular, epigenetic, and functional characterization. However, the two classifications have some limitations. They lack a prospective validation on a large scale, including patients from other geographic regions of the world. The differences between them are greater than similarities, which include differences in molecular mechanisms, relation to prognosis, and the distribution of Lauren\'s diffuse subtype among the four subgroups. Neither of them considers active and nonmalignant stromal cells. Stromal gene expression profiles may influence assignment to a specific subtype. On the other hand, novel stromal‐based signatures have been related to the dominant cancer phenotypes. Thus, the classification of GC can be improved from a tumor stroma perspective.[43](#cam42497-bib-0043){ref-type="ref"}, [44](#cam42497-bib-0044){ref-type="ref"}, [45](#cam42497-bib-0045){ref-type="ref"}

Although these subtypes may be related to the prognosis of GC patients and determine the patient\'s benefits from adjuvant chemotherapy after large‐scale validation trials, they do not take into account predisposing inherited germline variants for cancer. Recent data have shown that somatic cancer genes also show recessive rare, damaging germline variants (RDGVs) that predispose to cancer via a two‐hit mechanism.[46](#cam42497-bib-0046){ref-type="ref"} This indicates a possible interaction of the germline variants with somatic driver alterations in carcinogenesis. For example, germline variants in RBFOX1, a gene encoding an RNA‐binding protein involved in splicing, increase the incidence of SF3B1 somatic mutation by eightfold. Similarly, 19p13.3 variants are associated with a fourfold increase in somatic mutation rate of the PTEN tumor suppressor gene.[47](#cam42497-bib-0047){ref-type="ref"} However, the impact of large‐scale tumor sequencing has been limited in identifying cancer predisposition genes (CPGs).

6.2. Single‐nucleotide polymorphisms in CGA {#cam42497-sec-0008}
-------------------------------------------

Single‐nucleotide polymorphisms (SNPs) are natural genetic changes occurring with different frequencies in various populations. Some SNPs may change the gene expression profile and influence function of the gene, leading to risen susceptibility risk to the range of some disorders, like cancer. There are many instances of polymorphic genes, which raise the susceptibility to GC.

### 6.2.1. PRKAA1 {#cam42497-sec-0009}

One SNP, rs10074991 in PRKAA1 at 5p13.1, reached genome‐wide significance for CGA. PRKAA1 protein is a catalytic subunit of AMP‐activated protein kinase (AMPK), crucial for the regulation of cellular energy metabolism. To respond to the decline of intracellular ATP levels, AMPK stimulates energy‐production pathways and prevents processes of energy consuming leading to the inhibition of biosynthesis of protein, carbohydrate, and lipid, and prevention of cell growth and proliferation.[48](#cam42497-bib-0048){ref-type="ref"}

### 6.2.2. MUC1 and PLCE1 {#cam42497-sec-0010}

The glycoprotein Mucin 1 is aberrantly glycosylated and overexpressed in epithelial cancers, and plays an important role in disease progression.[49](#cam42497-bib-0049){ref-type="ref"} Phospholipase C epsilon‐1 (PLCE1) is a phospholipase C isoenzyme encoded by PLCE1 gene, it interacts with the proto‐oncogene Ras among other proteins. PLCE1‐related signaling network affects many critical carcinogenetic processes like metabolism, proliferation, survival, and tumor growth. In a genome‐wide association study (GWAS) conducted among Chinese people, positive correlations among SNPs in MUC1 and CGA and NCGA were similar. Two independent GWAS datasets in Chinese showed associations between multiple variants at 10q23, on gene PLCE1, and CGA risk.[50](#cam42497-bib-0050){ref-type="ref"}, [51](#cam42497-bib-0051){ref-type="ref"}

### 6.2.3. NF‐κBs {#cam42497-sec-0011}

NF‐κBs are stimulated in many cancers, the equivalent of "nonclassical oncogene." The combined effect analysis revealed that when carrying the *NFKBIA* gene polymorphism site of rs696 (AA) and *NFKB1* gene polymorphism site of rs3755867 (GG), the CGA incidence risk was more than the time the adverse genotype (OR = 5.22) was not carried.[52](#cam42497-bib-0052){ref-type="ref"}

### 6.2.4. IL1B‐31C, IL1B‐511T, and IL1RN2 {#cam42497-sec-0012}

Non‐Asian populations also showed augmented risks among IL1B‐31C, IL1B‐511T, and IL1RN2 carriers for CGA, but this was not significant in Asian populations.[53](#cam42497-bib-0053){ref-type="ref"}

### 6.2.5. P27 (kip1) {#cam42497-sec-0013}

The p27kip1 expression is an early event in gastric tumorigenesis, and is regarded as a candidate molecular biomarker for early GC.[54](#cam42497-bib-0054){ref-type="ref"} P27 (kip1) polymorphisms may be associated with the CGA susceptibilities in North China.

### 6.2.6. MTHFR {#cam42497-sec-0014}

The enzyme methylenetetrahydrofolate reductase (MTHFR) has an important role in the regulation of methionine and homocysteine concentrations in folate metabolism.[55](#cam42497-bib-0055){ref-type="ref"} Individuals with the MTHFR 677TT variant genotype possessed a twofold increased CGA risk (OR = 2.04).[56](#cam42497-bib-0056){ref-type="ref"}

### 6.2.7. ADPRT {#cam42497-sec-0015}

A study showed ORs of 2.17 and 1.61 for CGA in the ADPRT (Adenosine diphosphate ribosyl transferase) Ala/Ala or XRCC1 (X‐ray repair cross‐complementing 1) Gln/Gln genotype carriers, respectively, compared to noncarriers. Gene‐gene interaction of XRCC1 and ADPRT polymorphisms raised the OR of CGA in a hasty manner (OR for the combined XRCC1 Gln/Gln and ADPRT Ala/Ala genotypes was 6.43).[57](#cam42497-bib-0057){ref-type="ref"}

### 6.2.8. COX‐2 {#cam42497-sec-0016}

COX‐2, a major enzyme converting arachidonate to prostaglandins, is not present in normal cells unless quickly stimulated by different carcinogens. The level of COX‐2 was considerably increased in gastrointestinal cancer.[58](#cam42497-bib-0058){ref-type="ref"} Multivariate logistic regression analysis showed that the −1195AA, −765GC, and 587Arg/Arg genotypes of COX‐2 were related with increased CGA risk (OR = 1.50, OR = 2.06, and OR = 1.67, respectively). These results showed that the functional polymorphisms of COX‐2, when interacting with smoking, have an influential impact on developing CGA.[59](#cam42497-bib-0059){ref-type="ref"}

### 6.2.9. MDM2 {#cam42497-sec-0017}

Some epidemiological studies have found an association between murine double minute 2 (MDM2) SNP309 and the risk of different cancer types. TP53 induces intracellular expression of MDM2, whereas the latter induces the downregulation of TP53, the auto‐regulatory feedback loop between TP53 and MDM2. The relationship between MDM2 SNP309 and GC risk was meaningful, especially in CGA for the *H pylori*‐positive population group.[60](#cam42497-bib-0060){ref-type="ref"} Genotype analyses demonstrated that increased risk for development of CGA was correlated with the MDM2 309G and the P53 72Pro allele compared to the P53 72Arg allele and the MDM2 309T in an allele dose‐dependent manner.[61](#cam42497-bib-0061){ref-type="ref"}

### 6.2.10. RANK {#cam42497-sec-0018}

Overexpression of receptor activator of nuclear factor κ B (RANK) directly induces epithelial‐to‐mesenchymal transition and stem‐like phenotypes in tumor cells and normal mammary epithelial cells. The RANK/ RANKL/OPG system, mechanistically, affects tumor cell invasion and migration.[62](#cam42497-bib-0062){ref-type="ref"} RANK rs1805034 T\>C correlates with susceptibility to CGA, which is more obvious in elderly patients, male patients, smokers, and patients with no alcohol consumption.[63](#cam42497-bib-0063){ref-type="ref"}

### 6.2.11. PD‐1 {#cam42497-sec-0019}

Programmed cell death‐1 (PD‐1) is a major preventer of antitumor responses; it is a cogent candidate for genetic risk of subjects to many malignancies. Two ligands of PD‐1, programmed death‐1 ligand 1 (PD‐L1) and PD‐L2, inhibit activation and proliferation of T cells, leading to tumor escape from immune surveillance.[64](#cam42497-bib-0064){ref-type="ref"} A considerable increased risk of CGA related with the PD‐1 rs2227982 C\>T polymorphism was observed among ever drinking subjects (TT vs CC: OR = 2.53, TT+CT vs CC: OR = 2.04).[65](#cam42497-bib-0065){ref-type="ref"} According to *TCGA*, *PD‐L1* gene was frequently amplified in EBV‐positive GC, probably indicating the higher immunogenicity of this GC subclass. Amplification of a chromosomal region 9p24.1 (locus of PD‐L1 and PD‐L2) has been seen at 15% of EBV‐positive GC.[66](#cam42497-bib-0066){ref-type="ref"}

### 6.2.12. MYT1 {#cam42497-sec-0020}

MYT/NZF family transcription factors include two major members, myelin transcription factor 1 (MYT1, or neural zinc finger 2 (NZF2)) and its homologue MYT1‐like (MYT1L or NZF1); each of them has six copies of a ZnF including a C~2~HC consensus sequence. MYT1 is also related with carcinoma.[67](#cam42497-bib-0067){ref-type="ref"} MYT1L rs17039396 variants could be a suitable prognostic indicator for GC, especially among the CGA.[68](#cam42497-bib-0068){ref-type="ref"}

### 6.2.13. XPG {#cam42497-sec-0021}

XPG gene (or ERCC5) affects the excision of an \*24‐32 bp DNA segment having the bulky adduct in nucleotide excision repair (NER). The T/T genotype of XPG and rs751402 C/T SNP T allele was correlated with an increased CGA risk in younger subjects (≤61 years; OR = 1.33). The T/T genotype carriers must receive periodic upper gastrointestinal endoscopy to facilitate the early diagnosis and cure of CGA.[69](#cam42497-bib-0069){ref-type="ref"}

### 6.2.14. MMP‐2 {#cam42497-sec-0022}

Matrix metalloproteinase‐2 (MMP‐2) is mainly responsible for regulating inflammatory response.[70](#cam42497-bib-0070){ref-type="ref"} People with the CC genotype of MMP‐2 had \>threefold augmented risk (OR = 3.36) for development of CGA in comparison to those with the variant CT or TT genotype.[71](#cam42497-bib-0071){ref-type="ref"} MMP‐2 C−1306T polymorphism is a risk factor for CGA and the multifactor interactions among polymorphisms in FASL, MMP‐2, and FAS affect the CGA development.[72](#cam42497-bib-0072){ref-type="ref"} The detailed information regarding the genetic factors of CGA are indicated in Table [1](#cam42497-tbl-0001){ref-type="table"}.

###### 

Role of genetic factors in CGA

                          Case/control   *P*‐value        OR (95% CI)          Ref.
  ----------------------- -------------- ---------------- -------------------- -----------------------------------------------------------------------------------------
  PRKAA1 (rs10074991)     3042/7548      7.36 × 10^−12^   0.83 (0.79‐0.88)     \[ [48](#cam42497-bib-0048){ref-type="ref"}\]
  MUC‐1                                                                        \[ [50](#cam42497-bib-0050){ref-type="ref"}\]
  rs4072037 (A\>G)        1213/3302      9.5 × 10^−5^     0.75 (0.62‐0.87)      
  rs4460629 (C\>T)                       1.3 × 10^−4^     0.74 (0.64‐0.86)      
  PLCE1                                                                        \[ [50](#cam42497-bib-0050){ref-type="ref"}, [51](#cam42497-bib-0051){ref-type="ref"}\]
  rs2274223 (A\>G)        2766/ 11013    1.7 × 10^−39^    1.55 (1.45‐1.66)      
  rs2274223 (A\>G)                       4.2 × 10^−15^    1.57 (1.40‐1.76)      
  rs3765524 (C\>T)        1213/3302      7.4 × 10^−15^    1.56 (1.40‐1.75)      
  rs3781264 (T\>C)                       1.1 × 10^−13^    1.60 (1.41‐1.81)      
  rs11187842 (C\>T)                      7.1 × 10^−12^    1.63 (1.42‐1.87)      
  rs753724 (G\>T)                        8.0 × 10^−12^    1.63 (1.42‐1.87)      
  NFKBIA (rs696 AA)       NA             \<.05            5.22 (1.10, 24.92)   \[ [52](#cam42497-bib-0052){ref-type="ref"}\]
  NFKB1 (rs3755867 GG)                                                          
  P27(kip1) V/V           256/437        \<.05            2.56 (1.06‐4.78)     \[ [54](#cam42497-bib-0054){ref-type="ref"}\]
  MTHFR‐ 677TT            217/468        \<.05            2.04 (1.28‐3.26)     \[ [56](#cam42497-bib-0056){ref-type="ref"}\]
  ADPRT (Ala/Ala)         500/1000       .017             2.17 (1.55‐3.04)     \[ [57](#cam42497-bib-0057){ref-type="ref"}\]
  XRCC1 (Gln/Gln)                        \<.0001          1.61 (1.06 ‐2.44)     
  COX‐2                                                                        \[ [59](#cam42497-bib-0059){ref-type="ref"}\]
  1195AA                  357/985        .038             1.50 (1.05‐2.13)      
  765GC                                  .009             2.06 (1.29‐3.29)      
  587Arg/Arg                             .033             1.67 (1.04‐2.66)      
  MDM2 ‐309                                                                    \[ [60](#cam42497-bib-0060){ref-type="ref"}\]
  GG vs TT                999/2322       \<.05            2.00 (1.61‐2.50)      
  GT vs TT                                                1.50 (1.20‐1.88)      
  RANK (rs1805034 T\>C)                                                        \[ [63](#cam42497-bib-0063){ref-type="ref"}\]
  TC vs TT                323/592        .026             NR                    
  CC vs TT                               .0003            NR                    
  TC/CC vs TT                            .0019            NR                    
  CC vs TT/TC                            .002             NR                    
  PD‐1 (rs2227982 C\>T)                                                        \[ [65](#cam42497-bib-0065){ref-type="ref"}\]
  TT vs CC                330/608        .028             2.53 (1.11‐5.79)      
  TT+CT vs CC                            .047             2.04 (1.01‐4.13)      
  MYT1L (rs17039396 GG)   174/90         .001             NR                   \[ [68](#cam42497-bib-0068){ref-type="ref"}\]
  XPG (rs751402)                                                               \[ [69](#cam42497-bib-0069){ref-type="ref"}\]
  C/T                     212/216        \<.05            1.33 (1.00‐1.76)      
  T/T                                    .05              1.77 (1.12‐3.30)      
  MMP2 −1306CC            356/789        \<.05            3.36 (2.34‐4.97)     \[ [71](#cam42497-bib-0071){ref-type="ref"}\]
  MMP‐2 −1306CC                                                                 
  FASL‐ 844TT or TC       344/324        \<.05            4.58 (2.07‐10.14)     
  FAS‐ 1377AA                                                                  \[ [72](#cam42497-bib-0072){ref-type="ref"}\]

Abbreviations: NA, not available; NR, not reported; SNP, single‐nucleotide polymorphism.
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7. EPIGENETIC RISK FACTORS {#cam42497-sec-0023}
==========================

Promoter CpG island hypermethylation is popular in human cancers and correlates with transcriptional silencing of the associated gene.[73](#cam42497-bib-0073){ref-type="ref"} RASSF1A is placed on 3p21.3 and regulates apoptosis, cell cycle, microtubule stability, and other physiological activities. Epigenetic silencing of RASSF1A gene expression through promoter hypermethylation affects CGA. The RASSF1A gene\'s promoter methylation increased the CGA risk significantly (OR = 7.50).[74](#cam42497-bib-0074){ref-type="ref"} The CpG island hypermethylation at the promoter region of HLTF has also been found in the colon and stomach cancers, manifesting that aberrant methylation of HLTF affects carcinogenesis. HLTF methylation may be present in gastric cardia dysplasia phases and may affect the CGA development in subjects with a family history of UGIC.[75](#cam42497-bib-0075){ref-type="ref"} The impact of TSP1 on cancer progression is still controversial and shows stimulatory and inhibitory effects. Epigenetic silencing of TSP1 gene via promoter hypermethylation can affect CGA.[76](#cam42497-bib-0076){ref-type="ref"} CAV1 may regulate multiple intracellular signaling pathways. CAV1 expression loss with aberrant promoter methylation was detected in some human cancers. The CpG island shore methylation of CAV1 possibly affects the CGA progression and is a prognostic methylation biomarker for CGA cases.[77](#cam42497-bib-0077){ref-type="ref"}

The loss of p16 (INK4A) protein expression can be detected in 45% of cardiac, esophageal, and gastric adenocarcinoma and correlates with p16 (INK4A) gene hypermethylation. Methylation of CpG in the EBV‐positive class is even greater than that in the MSI class. Moreover, viral cancers have a unique pattern of downregulation‐related methylation of CDKN2A (p16). Hypermethylation of p16 (INK4A) is a common research outcome in CGA.[78](#cam42497-bib-0078){ref-type="ref"} The proximal promoter aberrant hypermethylation and MEG3 enhancer region were seen in tissues of CGA. Also, the enhancer region and proximal promoter hypermethylation and dysregulation of MEG3 and miR‐770 were correlated with a survival of poorer CGA patients.[79](#cam42497-bib-0079){ref-type="ref"} Aberrant hypermethylation‐mediated downregulation of C5orf66‐AS1 may play critical roles in CGA tumorigenesis and C5orf66‐AS1 can be a prognostic marker in the prediction of CGA patients\' survival.[80](#cam42497-bib-0080){ref-type="ref"} Epigenetic silencing of Wnt‐antagonist gene expression via promoter hypermethylation can influence CGA.[81](#cam42497-bib-0081){ref-type="ref"}

Being land of E‐cadherin gene, high methylation status of 5\' CPG may be a mechanism in developing CGA.[82](#cam42497-bib-0082){ref-type="ref"} A recent study indicated that there were a lot of males with CGA characterized by higher GATA5 DNA methylation values.[83](#cam42497-bib-0083){ref-type="ref"} FBXO32 (atrogin‐1) is an Fbox protein family member and has one of the four subunits of the ubiquitin protein ligase complex, contributing to muscle atrophy.[84](#cam42497-bib-0084){ref-type="ref"} Aberrant hypermethylation of FBXO32 is a mechanism resulting in loss or downexpression of the gene in CGA. FBXO32 is assumed as a functional tumor suppressor, and FBXO32 gene reactivation may have a therapeutic potential, indicating its role as a prognostic marker for CGA cases.[85](#cam42497-bib-0085){ref-type="ref"} It is demonstrated that the loss of RKIP expression and hypermethylation can be regarded as a marker to anticipate clinical result of CGA. It is suggested that RKIP is a new candidate gene among metastasis suppressors.[86](#cam42497-bib-0086){ref-type="ref"} The detailed information regarding the epigenetic factors of CGA are indicated in Table [2](#cam42497-tbl-0002){ref-type="table"}.

###### 

Role of epigenetic factors in CGA

                           Case/control   *P*‐value       OR (95% CI)          Ref.
  ------------------------ -------------- --------------- -------------------- -----------------------------------------------
  RASSF1A                  92/30          \<.001          7.50 (2.78‐20.23)    \[ [74](#cam42497-bib-0074){ref-type="ref"}\]
  HLTF                     96/96          \<.05           NR                   \[ [75](#cam42497-bib-0075){ref-type="ref"}\]
  TSP1                     96/96          \<.001          NR                   \[ [76](#cam42497-bib-0076){ref-type="ref"}\]
  CAV1                     172/172        \<.001          NR                   \[ [77](#cam42497-bib-0077){ref-type="ref"}\]
  p16^INK4A^               50/50          .002            NR                   \[ [78](#cam42497-bib-0078){ref-type="ref"}\]
  MEG3                     134/134        \<.001          NR                   \[ [79](#cam42497-bib-0079){ref-type="ref"}\]
  C5orf66‐AS1              125/125        \<.001          NR                   \[ [80](#cam42497-bib-0080){ref-type="ref"}\]
  Wnt‐antagonist genes                                                         
  sFRP1                    94/94          .000            NR                   \[ [81](#cam42497-bib-0081){ref-type="ref"}\]
  sFRP 2                                  .001            NR                    
  sFRP 4                                  .000            NR                    
  sFRP 5                                  .000            NR                    
  Wif‐1                                   .000            NR                    
  Dkk3                                    .000            NR                    
  E‐cadherin               92/92          \<.001          NR                   \[ [82](#cam42497-bib-0082){ref-type="ref"}\]
  GATA5                    105/105        \<.05           NR                   \[ [83](#cam42497-bib-0083){ref-type="ref"}\]
  FBXO32                   139/139        \<.001          NR                   \[ [85](#cam42497-bib-0085){ref-type="ref"}\]
  RKIP                     145/145        .000            NR                   \[ [86](#cam42497-bib-0086){ref-type="ref"}\]
  miR‐25/miR‐93/miR‐106b                                                       
  rs1534309                107/1284       5.38 × 10^−3^   0.56 (0.37‐0.86)     \[ [87](#cam42497-bib-0087){ref-type="ref"}\]
  rs2070215                               .0421           1.37 (5 1.02‐1.85)    

Abbreviations: NA, not available; NR, not reported; SNP, single‐nucleotide polymorphism.
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8. LONG NONCODING RNAs {#cam42497-sec-0024}
======================

Long noncoding RNAs (lncRNAs) are transcribed RNAs longer than 200 nt which lack an open reading frame of considerable length. lncRNAs are expressed at lower levels compared to mRNAs. lncRNAs' ectopic expression influences the GC development.[88](#cam42497-bib-0088){ref-type="ref"} There are not many articles on the variations of lncRNAs and the risk of CGA development. Notable downregulation of LOC100130476 was observed in primary CGA tissues, and SGC‐7901 and BGC‐823 cell lines. LOC100130476 can function as a tumor inhibitor gene in carcinogenesis of CGA. Aberrant methylation at the CpG sites next to the transcription start site within exon 1 might be important for gene silencing. LOC100130476 ectopic expression is considered a new biomarker for the early diagnosis of GC.[89](#cam42497-bib-0089){ref-type="ref"} C5orf66‐AS1 was considerably downregulated in cell lines and CGA tissues, and the level of expression was correlated with lymph node metastasis, pathological differentiation, TNM stage, and distant metastasis or recurrence.[90](#cam42497-bib-0090){ref-type="ref"} Table [3](#cam42497-tbl-0003){ref-type="table"} shows the results obtained from microarray analysis of lncRNAs in CGA.

###### 

Role of ncRNAs in promoting CGA

                              Expression changes   Case/control   *P*‐value   Fold change (log2)                                           Ref.
  --------------------------- -------------------- -------------- ----------- ------------------------------------------------------------ -----------------------------------------------
  LncRNAs                                                                                                                                  
  C5orf66‐AS1                 Downregulated        125/125        \<.01       NA                                                           \[ [80](#cam42497-bib-0080){ref-type="ref"}\]
  LOC100130476                Downregulated        121/121        .013        1.907 (1.148‐3.166)[a](#cam42497-note-0004){ref-type="fn"}   \[ [89](#cam42497-bib-0089){ref-type="ref"}\]
  ASHG19A3A028863             Upregulated          12/12          \<.05       169.6730934                                                  \[ [90](#cam42497-bib-0090){ref-type="ref"}\]
  ASHG19A3A040903             Upregulated                                     41.90954829                                                   
  ASHG19A3A041865             Upregulated                                     39.16918169                                                   
  ASHG19A3A018727             Upregulated                                     28.88943866                                                   
  ASHG19A3A052295             Upregulated                                     24.55914831                                                   
  GUST‐20‐P1426265844         Upregulated                                     22.40102966                                                   
  ASHG19A3A041043             Upregulated                                     20.64951965                                                   
  ASHG19A3A033911             Upregulated                                     15.82403426                                                   
  ASHG19A3A026346             Upregulated                                     15.43079683                                                   
  ASHG19A3A007184             Downregulated                                   59.38580626                                                   
  ASHG19A3A018598             Downregulated                                   15.16286445                                                   
  ASHG19A3A038967             Downregulated                                   9.499758688                                                   
  ASHG19A3H0000023            Downregulated                                   9.473660683                                                   
  ASHG19A3A018662             Downregulated                                   9.338922844                                                   
  ASHG19A3A007413             Downregulated                                   8.588461452                                                   
  ASHG19A3A011053             Downregulated                                   7.817390602                                                   
  ASHG19A3A035937             Downregulated                                   7.2417301                                                     
  ASHG19A3A055173             Downregulated                                   5.954896947                                                   
  ASHG19A3A0001119            Downregulated                                   4.960711075                                                   
  Micro RNAs                                                                                                                               
  miR‐770                     Downregulated        134/134        \<.01       NR                                                           \[ [79](#cam42497-bib-0079){ref-type="ref"}\]
  miR‐141                     Downregulated        41/41          \<.05       NR                                                           \[ [91](#cam42497-bib-0091){ref-type="ref"}\]
  miR‐203a                    Downregulated        127/127        .033        1.77 (1.046‐3.011)[a](#cam42497-note-0004){ref-type="fn"}    \[ [92](#cam42497-bib-0092){ref-type="ref"}\]
  miR‐107 (rs2296616 TC/CC)   Upregulated          NA             NR          1.49 (1.01‐2.20)[b](#cam42497-note-0005){ref-type="fn"}      \[ [93](#cam42497-bib-0093){ref-type="ref"}\]
  miR‐3656                    Downregulated        21/21          1.89E−16    −3.29535                                                     \[ [94](#cam42497-bib-0094){ref-type="ref"}\]
  miR‐378c                    Downregulated                       8.96E−14    −1.80765                                                      
  miR‐628‐3p                  Downregulated                       2.23E−13    −2.03238                                                      
  miR‐US33‐3p                 Downregulated                       2.67E−13    −2.25544                                                      
  miR‐148a‐3p                 Downregulated                       2.67E−13    −1.63085                                                      
  miR‐H10                     Downregulated                       4.43E−13    −2.84551                                                      
  miR‐638                     Downregulated                       8.99E−13    −1.55968                                                      
  miR‐483‐5p                  Downregulated                       2.20E−12    −1.35334                                                      
  miR‐675‐5p                  Downregulated                       5.11E−12    −1.70156                                                      
  miR‐1184                    Downregulated                       2.67E−11    −1.00147                                                      
  miR‐299‐5p                  Downregulated                       3.05E−11    −1.66357                                                      
  miR‐4285                    Downregulated                       4.74E−11    −1.06365                                                      
  miR‐3665                    Downregulated                       9.57E−11    −1.95478                                                      
  miR‐H25                     Downregulated                       1.04E−10    −1.61128                                                      
  miR‐H17                     Downregulated                       1.41E−10    −1.53334                                                      
  miR‐3195                    Downregulated                       1.41E−10    −1.28305                                                      
  miR‐518e‐5p                 Downregulated                       1.41E−10    −0.97021                                                      
  miR‐3196                    Downregulated                       7.06E−10    −2.64801                                                      
  miR‐30d‐5p                  Downregulated                       7.06E−10    −0.74407                                                      
  miR‐3124‐5p                 Downregulated                       2.21E−09    −2.60563                                                      
  miR‐196a‐5p                 Upregulated                         3.36E−14    4.111534                                                      
  miR‐135b‐5p                 Upregulated                         2.67E−13    2.555514                                                      
  miR‐2355‐3p                 Upregulated                         2.68E−13    1.517697                                                      
  miR‐4307                    Upregulated                         1.05E−09    2.371521                                                      
  miR‐1244                    Upregulated                         3.68E−09    2.409671                                                      
  miR‐892a                    Upregulated                         1.05E−08    1.8554                                                        
  miR‐20a‐5p                  Upregulated                         1.15E−08    1.501549                                                      
  miRPlusA1087                Upregulated                         6.38E−08    2.115592                                                      
  miR‐93‐5p                   Upregulated                         1.06E−07    1.5392                                                        
  miR‐455‐3p                  Upregulated                         1.80E−07    1.568063                                                      
  miR‐105‐5p                  Upregulated                         1.96E−07    1.755387                                                      
  miR‐764                     Upregulated                         2.58E−07    1.650002                                                      
  miR‐130b‐5p                 Upregulated                         4.98E−07    1.660447                                                      
  miR‐506‐3p                  Upregulated                         2.66E−06    1.605885                                                      
  miR‐454‐3p                  Upregulated                         3.92E−06    1.515466                                                      
  miR‐142‐3p                  Upregulated                         4.35E−06    1.524762                                                      
  miR‐3591‐3p                 Upregulated                         1.19E−05    1.452323                                                      
  miR‐196b‐5p                 Upregulated                         1.67E−05    1.682773                                                      
  miR‐3664‐5p                 Upregulated                         4.36E−05    1.737875                                                      
  miR‐636                     Upregulated                         9.98E−05    1.557929                                                      

Abbreviations: NA, not available; NR, not reported.

OR (95% CI).

Hazard ratio (HR).
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9. MICRORNAS {#cam42497-sec-0025}
============

MicroRNAs (miRNAs) are single‐stranded small (20‐22 nt) ncRNAs which regulate gene expression and contribute to a broad spectrum of biological processes like cell proliferation, differentiation, apoptosis, endothelial cell migration, and angiogenesis.[95](#cam42497-bib-0095){ref-type="ref"} Some studies reported that miR‐141 was decreased and correlated with lymph node metastases in CGA and advanced TNM stage. Additionally, miR‐141 may stop cell proliferation and trigger apoptosis in adenocarcinoma gastric cell line. Also, miR‐141 may directly stop MACC1 through binding to its 3\'‐UTR. It can affect the signaling pathways of MEK/ERK and p38 MAPK. It is a potential therapeutic goal for treating CGA cases.[91](#cam42497-bib-0091){ref-type="ref"} MEG3 and miR‐770 were notably downregulated in CGA patients and correlated with lymph node metastasis and TNM stage. The aberrant hypermethylation of the proximal promoter and MEG3 enhancer region was observed in CGA.[79](#cam42497-bib-0079){ref-type="ref"} Two tagSNPs of cluster 7.1 (miR‐25/miR‐93/miR‐106b) were found to be related with the GC cardia localization, rs2070215 (OR = 1.37) and rs1534309 (OR = 0.56).[87](#cam42497-bib-0087){ref-type="ref"} Significant downregulation and proximal promoter methylation of miR‐203b and miR‐203a in CGA were observed in CGA tissue. CGA cases in stage III and IV with decreased expression or hypermethylation of miR‐203a showed weak survival. MiR‐203b and miR‐203a may act as tumor suppressive miRNAs,miR‐203a reactivation may be regarded as a prognostic marker for CGA subjects.[92](#cam42497-bib-0092){ref-type="ref"} MiR‐107 is dysregulated in CGA pathogenesis, and the SNP rs2296616 may affect the process.[93](#cam42497-bib-0093){ref-type="ref"} It was found that four miRNAs (ie, miR‐3196, miR‐1244, miR‐135b‐5p, and miR‐628‐3p) were associated with differentiation of CGA. The miR‐196a‐5p was correlated with age of CGA onset. Survival analysis revealed that the miR‐135b‐5p expression level was correlated with survival of CGA.[94](#cam42497-bib-0094){ref-type="ref"} Table [3](#cam42497-tbl-0003){ref-type="table"} presents the results obtained from microarray analysis of miRNAs in CGA.

10. CONCLUSION {#cam42497-sec-0026}
==============

CGA is a multi‐factorial ailment and most cases are sporadic, although familial cases have been reported. There is much difference between CGA and NCGA in terms of tumor features, distinct etiological factors, and biological behaviors. Lifestyle, *H pylori* infection, GERD, and multiple genetic, epigenetic, and environmental risk factors have been related to an increased risk of CGA. However, several GWASs, followed by a large‐scale GWAS meta‐analysis, should be conducted to identify novel high‐penetrance genes and pathways as well as causal germline variants predisposing to CGA. They must include different ethnic groups, especially from high‐incidence countries for CGA, because some risk loci are ancestry‐specific.[96](#cam42497-bib-0096){ref-type="ref"}, [97](#cam42497-bib-0097){ref-type="ref"} In parallel, statistical methods can also be developed to identify CPGs from tumor sequencing data. Then, it should be largely explored how the genetic germline variants and somatic alterations interact to develop CGA in populations with different ethnic backgrounds. A little experiment has also been done on the impact of lncRNAs on the carcinogenesis of the CGA. Therefore, next‐generation high‐throughput RNA‐sequencing techniques can enable us to find novel ncRNA biomarkers related to the risk of CGA. Taken altogether, new cancer risk prediction models, including all genetic and nongenetic factors influencing risk should be developed to facilitate risk assessment, disease prevention, and early diagnosis and intervention of CGA in the future.
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